Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Avelumab · Bavencio, MSB-0010682

Monoclonal antibody · Antagonist of Programmed death-ligand 1 (CD274) · developed by Emd Serono

Approved FDA, Mar 2017
2 Registered trials

What is Avelumab?

Avelumab is a human IgG1 monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1 and B7.1 on T cells and antigen-presenting cells, restoring anti-tumor immune responses. It also induces antibody-dependent cell-mediated cytotoxicity against PD-L1-expressing cells. It is studied in epithelial ovarian cancer and non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Bavencio, MSB-0010682
Drug type
Monoclonal antibody
Targets
Programmed death-ligand 1 (CD274)
Mechanism
Antagonist of Programmed death-ligand 1 (CD274)
Pathways
PD-1/PD-L1 immune checkpoint signaling, T-cell activation, antibody-dependent cell-mediated cytotoxicity
Therapy area
Oncology
Developer
Emd Serono Inc
In trials of
IBRX, VSTM
FDA status
Approved as Bavencio (March 23, 2017), BLA761049 · FDA label
UNII
KXG2PJ551I

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 25, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03169790 Phase 1/2 Non Hodgkin Lymphoma Withdrawn IBRX
NCT02943317 Phase 1 Epithelial Ovarian Cancer Terminated VSTM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Epithelial Ovarian CancerNon Hodgkin Lymphoma

Other drugs acting on CD274

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.